

## Costanza Bogani - Short CV

### Personal data

Name: Costanza Bogani  
Date and place of birth: 02/10/1978, Prato (Italy)  
Citizenship: Italian  
Work address: Dip. Medicina Sperimentale e Clinica,  
University of Florence  
Largo Brambilla 3, 50134 Florence, Italy  
Phone: ++39 055 7947688  
FAX: ++39 055 7947688  
E-mail: [cbogani@hotmail.com](mailto:cbogani@hotmail.com)



### Education

February 24, 2009: PhD in Clinical and Experimental Oncology at the University of Florence. Thesis title: "Characterization of molecular alterations related to Myeloproliferative Neoplasms pathogenesis".  
January 28, 2004: graduated with 110/110 magna cum laude in Biological Sciences at the University of Florence, with the thesis "Trombopoietin effects on Myelofibrosis in GATA knock-down mice (GATA-1<sup>low</sup>)".

### Research experience

From November 2012. Scholarship AIL (SIES) on "Analysis of signaling pathways PI3K/AKT/mTOR and JAK/STAT in chronic Myeloproliferative Neoplasms in vitro and in vivo", Hematology Department, University of Florence, under the supervision of Professor AM. Vannucchi.  
January 2009-October 2012: Fellow in the Laboratory for the study of *Myeloproliferative Neoplasms (MPN)*, Hematology Department, University of Florence,  
May and November 2007. Visiting Scientist, INSERM 602, Institut André Lwoff Université Paris XI Hôpital Paul Brousse (director Dr. Marie-Caroline Le Bousse-Kerdilès), Villejuif, Paris.  
January 2006- December 2008. Post-doctoral School in Clinical and Experimental Oncology, University of Florence.  
January 2004- December 2005. Fellow in the Laboratory for the study of *Myeloproliferative Neoplasms*, Hematology Department, University of Florence, under the supervision of Professor AM. Vannucchi.

### Memberships

2006 : membership of the Italian Society of Experimental Hematology (SIES).  
2009 : membership of the Italian Society of Hematology (SIE).

### Technical skills and competences

Cell culture with cell lines and primary cell; proliferating assay with drugs alone or in combination using Origin Software and Calcsyn Software; migration assay; cell transfection with Amaxa Nucleofector technology; processing samples of peripheral blood and bone marrow; immunomagnetic separations with microbeads; flow cytometry analysis with winMDI software and FlowJo Software; gene expression using conventional PCR, Real Time PCR, single-colony genotyping, study of epigenetic aspects (Methylation specific PCR).

### Five selected publications

1. **Bogani C**, Bartalucci N, Martinelli S, et al, *mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms*. Plos One 2013; 8(1):e54826. Epub 2013 Jan 31.
2. **Bogani C**, Ponziani V, Guglielmelli P; et al, *Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis*. Myeloproliferative Disorders Research Consortium. Stem Cells. 2008 Aug;26(8):1920-30. Epub 2008 May 29.
3. Guglielmelli P, Tozzi L, Pancrazzi A, **Bogani C**, Antonioli E; et al. *MicroRNA expression profile in granulocytes from primary myelofibrosis patients*. MPD Research Consortium. Exp Hematol. 2007 Nov;35(11):1708-18.
4. **Bogani C**, Guglielmelli P, Antonioli E, Pancrazzi A, Bosi A, Vannucchi AM. *B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis*. Haematologica. 2007 Feb;92(2):258-9.

5. Martelli F, Ghinassi B, Panetta B, Alfani E, Gatta V, Pancrazzi A, **Bogani C**, Vannucchi AM, Paoletti F, Migliaccio G, Migliaccio AR. *Variation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds*. Blood. 2005 Dec 15;106(13):4102-13. Epub 2005 Aug 18.